Adam Hutchings

Learn More
OBJECTIVE To pilot the use of multicriteria decision analysis to establish and apply a framework of weighted attributes to value orphan medicinal products. METHODS Literature searches on the natural history and burden of 40 rare diseases and of how payers assess treatment value and three workshops with, respectively, GlaxoSmithKline managers working on(More)
BACKGROUND Orphan drugs are a growing issue of importance to European healthcare policy makers. The success of orphan drug legislation in Europe has resulted in an increasing number of licensed medicines for rare diseases, and many more yet unlicensed products have received orphan drug designation. Increasingly the concerns amongst policy makers relate to(More)
BACKGROUND The growth in expenditure on orphan medicinal products (OMP) across Europe has been identified as a concern. Estimates of future expenditure in Europe have suggested that OMPs could account for a significant proportion of total pharmaceutical expenditure in some countries, but few of these forecasts have been well validated. This analysis aims to(More)
In multiple myeloma (MM), health-related quality of life (HRQoL) data is becoming increasingly important, owing to improved survival outcomes and the impact of treatment-related toxicity on HRQoL. Researchers are more frequently including HRQoL assessments in clinical trials, but analysis and reporting of this data has not been consistent. A systematic(More)
SETTING Samara Oblast, Russia. OBJECTIVE To compare the rates of tuberculosis (TB) in health care workers (HCWs) working in TB services, general health services (GHS) and the general population in a region of the Russian Federation. DESIGN Analysis of notification rates of TB among HCWs, GHS workers and the general population during the 9-year period(More)
BACKGROUND Anemia is an important cause of morbidity in MDS patients, principally through increased cardiovascular disease. Transfusion status has been seen to be a significant prognostic factor for disease progression and mortality, yet the relationship between anemia levels and cardiovascular disease is not well understood. OBJECTIVE This study aimed to(More)
• It has been 15 years since the introduction of orphan medicinal product (OMP) legislation in the EU. Until 2014, one hundred and twelve orphan drugs had been approved in Europe1. • Orphan drugs represent a particular challenge to payers due to the large unmet patient need, paucity of disease information and high per-patient costs2. As of yet, there is no(More)
The holistic concept of Xhosa and Zulu traditional medicine and sorne differences from Western orthodox practice are briefly outlined. The transmission of herbal knowledge within various social groups is outlined. The background, training and sorne procedures followed by five of the informants are discussed. Plant characteristics that may be seen, felt,(More)
Background: The growth in expenditure on orphan medicinal products (OMP) across Europe has been identified as a concern. Estimates of future expenditure in Europe have suggested that OMPs could account for a significant proportion of total pharmaceutical expenditure in some countries, but few of these forecasts have been well validated. This analysis aims(More)